New hope for Hard-to-Treat colorectal cancer: targeted drug combo enters human trials
NCT ID NCT07653685
First seen Jun 19, 2026 · Last updated Jun 19, 2026
Summary
This study tests a new drug called TQB2930, which targets the HER2 protein on cancer cells, combined with standard chemotherapy and possibly another drug (bevacizumab). The goal is to find the safest and most effective dose and see if it shrinks tumors in people with advanced colorectal cancer that cannot be removed by surgery. About 71 participants aged 18-75 with HER2-positive disease will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Gansu Provincial Tumor Hospital
Lanzhou, Gansu, 730050, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Guangxi Zhuang Autonomous Region Cancer Hospital
Nanning, Guangxi, 530000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, 150000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Henan Cancer Hospital
Zhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hunan Cancer Hospital
Changsha, Hunan, 410013, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jiangsu Provincial Cancer Hospital
Nanjing, Jiangsu, 210000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jilin Cancer Hospital
Changchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Jingzhou First People's Hospital
Jingzhou, Hubei, 434099, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Liaoning Cancer Hospital & Institute
Shenyang, Liaoning, 110000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Lishui Municipal Central Hospital
Lishui, Zhejiang, 323000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Peking University First Hospital
Beijing, Beijing Municipality, 100034, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Renji Hospital, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, 563000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital of Xi'an Jiaotong University Medical College
Xi'an, Shaanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Air Force Medical University
Xi’an, Shanxi, 710000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Third People's Hospital of Zhengzhou
Zhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The first affiliated hospital of Zhengzhou university
Zhengzhou, Henan, 450000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The first hospital of Jilin University
Changchun, Jilin, 130021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Medical University Cancer Institute & Hospital
Tianjin, Tianjin Municipality, 300202, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tianjin Union Medical Center
Tianjin, Tianjin Municipality, 300121, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, Xinjiang, 830054, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhongda Hospital Southeast University
Nanjing, Jiangsu, 210009, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TQB2930 injection (a drug targeting HER2 protein on cancer cells) combined with chemotherapy (oxaliplatin, capecitabine) and possibly bevacizumab
What this could lead to
If successful, this could lead to a new treatment option for people with HER2-positive advanced colorectal cancer that has not responded to other therapies.
What could go wrong
This is an early-phase trial with only 71 participants, so results may not apply to everyone. The drug combination may cause side effects or not shrink tumors as hoped.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.